Related Experiment Video
Updated: Jan 18, 2026

09:25
Author Spotlight: Exploring Intrinsically Disordered Protein Dynamics Through NMR Relaxation Experiments
Published on: November 1, 2024
2.7K
Intrinsically disordered proteins and liquid-liquid phase separation in drug discovery.
Nilakshi Deka1, Niharika Nag2, Timir Tripathi1
1Molecular and Structural Biophysics Laboratory, Department of Zoology, School of Life Sciences, North-Eastern Hill University, Shillong 793022, India.
Drug Discovery Today
|January 16, 2026
Summary
Intrinsically disordered proteins (IDPs) drive liquid-liquid phase separation (LLPS) for cellular organization. Dysregulated LLPS links to diseases, spurring new therapeutic strategies targeting protein phase behavior.
Area of Science:
- Biochemistry and Molecular Biology
- Cell Biology
- Drug Discovery
Background:
- Intrinsically disordered proteins (IDPs) are crucial for cellular organization via liquid-liquid phase separation (LLPS).
- IDPs' dynamic nature enables the formation of biomolecular condensates (BCs), essential for biological processes.
- Dysregulation of LLPS by IDPs is implicated in diseases like cancer and neurodegeneration.
Purpose of the Study:
- To explore the role of IDPs and LLPS in cellular organization and disease.
- To review emerging therapeutic strategies targeting IDP-driven phase separation.
- To highlight challenges and future directions in modulating condensate behavior for treatment.
Main Methods:
- Review of current literature on IDPs, LLPS, and disease mechanisms.
- Analysis of novel therapeutic approaches, including small molecules, peptides, and PROTACs.
- Discussion of computational methods and AI in understanding IDP conformational landscapes.
Main Results:
- IDPs' conformational flexibility drives LLPS, forming functional BCs.
- Aberrant LLPS contributes to various pathologies, presenting therapeutic targets.
- Diverse strategies, from physicochemical modulators to targeted protein degradation, are being developed.
Conclusions:
- Targeting IDP-mediated LLPS offers a promising avenue for novel therapeutics.
- Overcoming challenges in IDP heterogeneity and condensate variability is key.
- Integrated advances in technology are essential for developing next-generation therapies.

